Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8386 to 8400 of 9130 results

  1. Bevacizumab for untreated malignant pleural mesothelioma [ID1183]

    Discontinued Reference number: GID-TA10197

    Technology appraisal guidance
    Discontinued

  2. Plitidepsin with dexamethasone for treating multiple myeloma after 3 previous therapies including bortezomib and lenalidomide [ID1081]

    Discontinued Reference number: GID-TA10171

    Technology appraisal guidance
    Discontinued

  3. Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]

    Discontinued Reference number: GID-TA10177

    Technology appraisal guidance
    Discontinued

  4. Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]

    Discontinued Reference number: GID-TA10322

    Technology appraisal guidance
    Discontinued

  5. Renal cell carcinoma - sunitinib [ID1076]

    Discontinued Reference number: GID-TA10166

    Technology appraisal guidance
    Discontinued

  6. Rucaparib for treating ovarian, fallopian tube or peritoneal cancer that has a BRCA mutation [ID1184]

    Discontinued Reference number: GID-TA10168

    Technology appraisal guidance
    Discontinued

  7. Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

    Discontinued Reference number: GID-HST10033

    Highly specialised technologies guidance
    Discontinued

  8. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued Reference number: GID-HST10038

    Highly specialised technologies guidance
    Discontinued

  9. Electrochemotherapy for the treatment of malignant melanoma

    Discontinued Reference number: GID-IP1041

    Interventional procedures guidance
    Discontinued

  10. MRI guided focussed ultrasound for chronic pain

    Discontinued Reference number: GID-IP1043

    Interventional procedures guidance
    Discontinued

  11. KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

    Discontinued Reference number: GID-DT14

    Diagnostics guidance
    Discontinued

  12. Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

    Discontinued Reference number: GID-DT9

    Diagnostics guidance
    Discontinued

  13. Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

    Discontinued Reference number: GID-HST10004

    Highly specialised technologies guidance
    Discontinued

  14. Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

    Discontinued Reference number: GID-HST10032

    Highly specialised technologies guidance
    Discontinued

  15. Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337]

    Discontinued Reference number: GID-TAG420

    Technology appraisal guidance
    Discontinued